Sink hypothesis and therapeutic strategies for attenuating Abeta levels.
about
The Rationale for Insulin Therapy in Alzheimer's DiseaseA novel monoclonal antibody against the N-terminus of Aβ1-42 reduces plaques and improves cognition in a mouse model of Alzheimer's disease.Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathyAnti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.Amyloid plaque pathogenesis in 5XFAD mouse spinal cord: retrograde transneuronal modulation after peripheral nerve injuryBrain transit and ameliorative effects of intranasally delivered anti-amyloid-β oligomer antibody in 5XFAD mice.Immunotherapeutic efficiency of a tetravalent Aβ1-15 vaccine in APP/PS1 transgenic mice as mouse model for Alzheimer's diseaseSustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β.PPARγ agonists regulate bidirectional transport of amyloid-β across the blood-brain barrier and hippocampus plasticity in db/db mice.Can insulin signaling pathways be targeted to transport Aβ out of the brain?Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes MellitusSafety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: A Systematic Review and Meta-Analysis.Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.Can brain impermeable BACE1 inhibitors serve as anti-CAA medicine?APOE3, but not APOE4, bone marrow transplantation mitigates behavioral and pathological changes in a mouse model of Alzheimer diseaseAnti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise.RAGE-NF-κB-PPARγ Signaling is Involved in AGEs-Induced Upregulation of Amyloid-β Influx Transport in an In Vitro BBB Model.Preparation of Selenoinsulin as a Long-Lasting Insulin Analogue.
P2860
Q26744834-0B3C291C-CF09-48E0-88AD-9B08049F4768Q33853280-321E21F0-C1D0-480C-ACB0-D0754CD5D411Q34973787-F1A6054B-DE37-4488-9873-1F632C6DED43Q35058359-44658FF3-E7C0-4410-8D2A-75BEE7099D6AQ36586319-3BE23CC8-D299-4B6E-8187-FB4336FEB6EBQ37042410-65F96286-C5D0-4202-9183-F2291C9F4256Q37530061-29EE8611-DE0F-46DF-B3A8-7A10B1F1B24FQ37556990-69EBD850-37CD-47AF-BFB4-FD8530C76B26Q37686110-3B396F56-B707-4679-AA28-586187328443Q38542045-6DA9F5F6-1166-4E8E-A8A2-9BB00E0757AFQ38664408-60B9E605-CDAD-4CF4-AF8C-967818B05F8FQ39057175-F394E6FA-8302-49AC-AC52-E2C036C3DE6CQ39139894-6AFA87F2-5C13-4537-879E-FB6BFF932C61Q41542097-80FE5811-41C9-4FBD-A718-689C7516276BQ41866014-279AD443-DFCE-487C-A9F5-FFA78659E608Q46297382-A4145BC7-E119-4E1B-8E61-9D1A96E421B5Q48127081-B5F6136F-D30B-4609-930B-27A9B28158E2Q48296760-941095AA-1089-4C5C-BA19-C43F57398CAF
P2860
Sink hypothesis and therapeutic strategies for attenuating Abeta levels.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sink hypothesis and therapeutic strategies for attenuating Abeta levels.
@en
Sink hypothesis and therapeutic strategies for attenuating Abeta levels.
@nl
type
label
Sink hypothesis and therapeutic strategies for attenuating Abeta levels.
@en
Sink hypothesis and therapeutic strategies for attenuating Abeta levels.
@nl
prefLabel
Sink hypothesis and therapeutic strategies for attenuating Abeta levels.
@en
Sink hypothesis and therapeutic strategies for attenuating Abeta levels.
@nl
P2860
P356
P1433
P1476
Sink hypothesis and therapeutic strategies for attenuating Abeta levels.
@en
P2093
Daniel H S Lee
P2860
P304
P356
10.1177/1073858410381532
P577
2011-02-16T00:00:00Z